Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05797506 · ClinicalTrials.gov registry record · Phase 2
Safety, Feasibility and Efficacy of Sulforaphane (Avmacol Extra Strength) in Chronic Kidney Disease
A Phase 2 study of Chronic Kidney Disease Stage 3 and Chronic Kidney Disease Stage 4, sponsored by University of Rochester.
- Active
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT05797506: Active Phase 2 study of Chronic Kidney Disease Stage 3 and Chronic Kidney Disease Stage 4, sponsored by University of Rochester.
NCT05797506 is a Phase 2 study of Chronic Kidney Disease Stage 3 and Chronic Kidney Disease Stage 4 that is active but no longer recruiting, run by University of Rochester. The registered enrollment target is 100 participants, below the 5,586-participant average among 4 other Chronic Kidney Disease Stage 3 trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05797506, a Phase 2 study of Chronic Kidney Disease Stage 3 and Chronic Kidney Disease Stage 4, is active but no longer recruiting, sponsored by University of Rochester.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The Sulforaphane Production System® in Avmacol Extra Strength (ES) supplies broccoli seed extract (glucoraphanin) and Myrosimax® (Active Myrosinase Enzyme) which helps promote sulforaphane production in your body. The investigators hypothesize that daily intake of Avmacol ES can decrease kidney disease progression rate and decrease markers of oxidative stress and inflammation in Chronic Kidney Disease (CKD) patients. They will test this hypothesis in a randomized, double-blind, placebo controlled Phase 2 clinical trial. This proposed study has been funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), R01 DK128677.
Primary Outcome
Plasma 8 isoprostane in picograms per milliliter was measured at baseline and at Months 1, 3, and 6. For each participant at each follow up visit, change from baseline was calculated as follow up value minus baseline value. Mean change and standard deviation are reported separately at Month 1, Month 3, and Month 6.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DRUG Sulforaphane (Avmacol Extra Strength)
Study Locations (1)
New York
- University of Rochester Medical Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-05-03 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
What the registry record for NCT05797506 still lists
NCT05797506 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 5,586-participant average among 4 other Chronic Kidney Disease Stage 3 trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Chronic Kidney Disease Stage 3 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05797506 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05797506 about?
NCT05797506 is a clinical study titled "Safety, Feasibility and Efficacy of Sulforaphane (Avmacol Extra Strength) in Chronic Kidney Disease". The Sulforaphane Production System® in Avmacol Extra Strength (ES) supplies broccoli seed extract (glucoraphanin) and Myrosimax® (Active Myrosinase Enzyme) which helps promote sulforaphane production in your body. The investigators hypothesize that daily intake of Avmacol ES can decrease kidney dise...
What is the current status of trial NCT05797506?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2023-05-03. Estimated completion is 2025-12-31.
What conditions does trial NCT05797506 study?
This clinical trial studies the following conditions: Chronic Kidney Disease Stage 3, Chronic Kidney Disease Stage 4.
What interventions are being tested in trial NCT05797506?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Sulforaphane (Avmacol Extra Strength) (DRUG).
Who is sponsoring clinical trial NCT05797506?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05797506 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Disease Stage 3
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety, Tolerability, and Preliminary Efficacy with AION-301 Administered by Intravenous Infusion Compared with Placebo Administered by Intravenous Infusion Investigational Intervention in Participants Aged 35 to 75 Years of Age with Chronic Kidney Disease (CKD)
RECRUITING · Phase 1
-
Prospective Decision Impact Clinical Utility Trial of KidneyIntelX
ACTIVE NOT RECRUITING
-
Preserving Kidney Function in Children With Chronic Kidney Disease
COMPLETED
-
Living With CKD: An E-Learning Platform for Adolescents With CKD About the Disease and Its Management
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI